Avacopan (granulomatosis with polyangiitis or microscopic polyangiitis; in combination with rituximab or cyclophosphamide)

Subject:

• Active Substance: Avacopan
• Name: Tavneos^®
• Therapeutic area: Granulomatosis with polyangiitis or microscopic polyangiitis
• Pharmaceutical company: Vifor Pharma Deutschland GmbH

Time table:

• Start: 15.02.2022
• Final decision by G-BA: 04.08.2022

Final decision:

• Hint for a minor additional benefit